Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the CNS caused by the human polyomavirus 2 (JCV). PML predominantly occurs in immunocompromised patients. To date, no specific antiviral treatment exists, leaving only restoration of the immune system as possible treatment. In 2019, the monoclonal antibody pembrolizumab was reported as a potential treatment option in PML in a case series. Following case reports could not thoroughly confirm a positive outcome. Pembrolizumab targets the inhibitory programmed cell death protein 1 (PD-1) receptor on lymphocytes and is associated with beneficial expansion of pre-existing virus-specific T cells. Here we describe a patient with PML who benefited from combined treatment with intravenous immunoglobulins, maraviroc, and pembrolizumab.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Case presentation
In May 2019, a 69-year-old Caucasian presented in our outpatient clinic with double vision, gait ataxia, motor dysfunction of the right hand, amnestic deficits, and dysarthria. Treatment with rituximab was administered from April 2015 until January 2018 and R-bendamustine from April 2015 until October 2015 due to follicular lymphoma, diagnosed in March 2015. Progressive multifocal leukoencephalopathy (PML) was diagnosed in July 2019 due to typical cerebral MRI lesions (Fig. 1A) and positive human polyomavirus 2 (JCV) PCR in cerebrospinal fluid (CSF). Total T cell and CD4+ T cell count at that time was 325 and 214 per microliter of blood. JCV-specific cells were detectable in both CD4 + and CD8 + T cells (Fig. 2). As a result of long-term treatment with rituximab, a deficiency of IgM- (0.16 g/l), IgA- (0.78 g/l), and IgG antibodies (8.58 g/l) was noted. In December 2019, treatment with intravenous immunoglobulins (ivIg) (2 g/kg over 5 days) followed by 7 courses of pembrolizumab (2 mg/kg) was induced. Time between each dose of pembrolizumab was 3–4 weeks. To prevent an immune reconstitution inflammatory syndrome (IRIS), the patient received additionally maraviroc 600 mg/day, a CCR5 antagonist that seems beneficial in PML-IRIS (Hodecker et al. 2017). Regular neurological examination did not show any neurological deterioration but rather a robust improvement of the previously mentioned deficits that was already noticeable after the first pembrolizumab cycle. Neuropsychological assessments using the Montreal Cognitive Assessment Scale (MoCA) demonstrated a cognitive improvement from initially 7 to 17 of 30 points. Initial MRI scans of the head in July 2019 showed T2w lesions biparietal and in the right cerebellar hemisphere (Fig. 1A). A follow-up MRI before the third pembrolizumab infusion in January 2020 showed a progress of the lesions as well as new subcortical lesions frontal and temporal (Figs. 1B and 3). Second PCR testing for JCV DNA in CSF was weakly positive with a viral load between 500 and 2500 copies per microliter. In MRI follow-ups in February 2020 (Fig. 1C) and at the end of treatment (Fig. 1D), some lesions had receded. After the sixth infusion of pembrolizumab, JCV DNA returned undetectable in the patient’s CSF and frequencies of JC virus–specific T cells were lower compared to baseline. The total T cell count was restored to 1,213 per microliter of blood with 768 CD4+ T cells per microliter.
Discussion
In this case, treatment with pembrolizumab might have supported pre-existing populations of JCV-specific T cells in fighting PML (Cortese et al. 2019; Tan et al. 2012), resulting in patient’s improvement. A case series published in 2019 showed a positive outcome of 5 of 8 patients with PML treated with pembrolizumab (Cortese et al. 2019). Combined with following case reports, until January 2021, 14 patients with PML due to lymphoproliferative disorders were treated with pembrolizumab (Cortese et al. 2019; Dufour et al. 2020; Holmes et al. 2020; Kapadia and Ney 2020; Mahler et al. 2020; Möhn et al. 2021; Rauer et al. 2019; Stögbauer et al. 2021). Of those, 9 patients stabilized or showed clinical improvement. Only 4 patients showed clinical or radiological signs of IRIS (Dufour et al. 2020; Möhn et al. 2021; Rauer et al. 2019). As IRIS is a possibly fatal complication in treating PML, we decided for additional treatment with maraviroc, a CCR5 antagonist that seems beneficial in PML-IRIS (Hodecker et al. 2017). Though there was slight gadolinium enhancement in an MRI during treatment (Fig. 3) as a possible subclinical sign of PML-IRIS (Wattjes et al. 2016), the patients’ symptoms did not deteriorate. No further contrast enhancement was detected in following MRI scans. To evaluate the effect of pembrolizumab in treating PML and the use of maraviroc in treating PML-IRIS, further studies with respect to the primary cause of immunodeficiency are warranted. Since prognosis of PML in patients with hematological malignancies is poor due to innate immunosuppression and respective immunomodulatory therapies (Neil and DeAngelis 2017), treatment of PML with pembrolizumab should be an option well considered.
References
Cortese I, Muranski P, Enose-Akahata Y, Ha S-K, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A (2019) Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380:1597–1605. https://doi.org/10.1056/NEJMoa1815039
Dufour I, Duprez T, Wertz M, Saussoy P, Ackermans N, El Sankari S, van Pesch V, van den Neste E (2020) Improvement in progressive multifocal leukoencephalopathy after pembrolizumab‐induced immune reconstruction inflammatory syndrome in a patient with follicular lymphoma. eJHaem 1:585–588. https://doi.org/10.1002/jha2.56
Hodecker SC, Stürner KH, Becker V, Elias-Hamp B, Holst B, Friese MA, Heesen C (2017) Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS. Neurol Neuroimmunol Neuroinflamm 4. https://doi.org/10.1212/NXI.0000000000000325
Holmes A, Wellings T, Walsh O, Rowlings P (2020) Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab. J Neurovirol. https://doi.org/10.1007/s13365-020-00899-0
Kapadia RK, Ney D (2020) Stabilization of progressive multifocal leukoencephalopathy after pembrolizumab treatment. Neurohospitalist 10:238–239. https://doi.org/10.1177/1941874420902872
Mahler C, Andrews M, Henson SM, Gnanapavan S (2020) Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm 7. https://doi.org/10.1212/NXI.0000000000000756
Möhn N, Wattjes MP, Adams O, Nay S, Tkachenko D, Salge F, Heine J, Pars K, Höglinger G, Respondek G, Stangel M, Skripuletz T, Jacobs R, Sühs K-W (2021) PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. Ther Adv Neurol Disord 14:175628642199368. https://doi.org/10.1177/1756286421993684
Neil EC, DeAngelis LM (2017) Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. Blood Adv 1:2041–2045. https://doi.org/10.1182/bloodadvances.2017008201
Rauer S, Marks R, Urbach H, Warnatz K, Nath A, Holland S, Weiller C, Grimbacher B (2019) Treatment of progressive multifocal leukoencephalopathy with pembrolizumab. N Engl J Med 380:1676–1677. https://doi.org/10.1056/NEJMc1817193
Stögbauer J, Schulz-Schaeffer W, Mühl-Benninghaus R, Lochner P (2021) Clinical and magnetic resonance imaging monitoring in progressive multifocal leukoencephalopathy treated with pembrolizumab: a case report. Neurol Sci 42:357–359. https://doi.org/10.1007/s10072-020-04582-4
Tan CS, Bord E, Broge TA, Glotzbecker B, Mills H, Gheuens S, Rosenblatt J, Avigan D (2012) Koralnik IJ (2012) Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr (1999) 60:244–248. https://doi.org/10.1097/QAI.0b013e31825a313c
Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BMJ, Barkhof F, Killestein J (2016) MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. J Neurol Neurosurg Psychiatry 87:879–884. https://doi.org/10.1136/jnnp-2015-311411
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Boesl, F., Allers, K., Herm, J. et al. Sequential treatment of progressive multifocal leukoencephalopathy with intravenous immunoglobulins and pembrolizumab. J. Neurovirol. 28, 335–338 (2022). https://doi.org/10.1007/s13365-022-01059-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13365-022-01059-2